Anemia, Refractory, with Excess of Blasts - 175 Studies Found
Completed |
: Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy :
: |
Terminated |
: A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia. : Acute Myeloid Leukemia : 2006-08-11 :
|
Recruiting |
: Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome :
|
Active, not recruiting |
: DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia :
|
Completed |
: Thalidomide in Treating Patients With Myelodysplastic Syndrome :
|
Completed |
: Tipifarnib in Treating Patients With Myelodysplastic Syndromes :
|
Completed |
: Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome :
: |
Completed |
: PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome :
: Drug: bortezomib Given IV Other Names: |
Recruiting |
: Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies :
|
Completed |
: Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies :
: |